Mostrar el registro sencillo del ítem
Artículo
Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality
dc.creator | Mora Romero, Bella | es |
dc.creator | Capelo Carrasco, Nicolás | es |
dc.creator | Pérez Moreno, Juan José | es |
dc.creator | Álvarez Vergara, María Isabel | es |
dc.creator | Trujillo Estrada, Laura Isabel | es |
dc.creator | Romero Molina, Carmen | es |
dc.creator | Martínez Márquez, Emilio | es |
dc.creator | Morano Catalan, Noelia | es |
dc.creator | Vizuete Chacón, María Luisa | es |
dc.creator | López Barneo, José | es |
dc.creator | Nieto González, José Luis | es |
dc.creator | García-Junco Clemente, Pablo | es |
dc.creator | Vitorica Ferrández, Francisco Javier | es |
dc.creator | Gutiérrez, Antonia | es |
dc.creator | Macías, David | es |
dc.creator | Rosales Nieves, Alicia E. | es |
dc.creator | Pascual Bravo, Alberto | es |
dc.date.accessioned | 2024-07-30T08:26:28Z | |
dc.date.available | 2024-07-30T08:26:28Z | |
dc.date.issued | 2024-07-24 | |
dc.identifier.citation | Mora Romero, B., Capelo Carrasco, N., Pérez Moreno, J.J., Álvarez Vergara, M.I., Trujillo Estrada, L.I., Romero Molina, C.,...,Pascual Bravo, A. (2024). Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality. Nature Metabolism. https://doi.org/10.1038/s42255-024-01081-0. | |
dc.identifier.issn | 2522-5812 | es |
dc.identifier.uri | https://hdl.handle.net/11441/161753 | |
dc.description.abstract | Primary mitochondrial diseases (PMDs) are associated with pediatric neurological disorders and are traditionally related to oxidative phosphorylation system (OXPHOS) defects in neurons. Interestingly, both PMD mouse models and patients with PMD show gliosis, and pharmacological depletion of microglia, the innate immune cells of the brain, ameliorates multiple symptoms in a mouse model. Given that microglia activation correlates with the expression of OXPHOS genes, we studied whether OXPHOS deficits in microglia may contribute to PMDs. We first observed that the metabolic rewiring associated with microglia stimulation in vitro (via IL-33 or TAU treatment) was partially changed by complex I (CI) inhibition (via rotenone treatment). In vivo, we generated a mouse model deficient for CI activity in microglia (MGcCI). MGcCI microglia showed metabolic rewiring and gradual transcriptional activation, which led to hypertrophy and dysfunction in juvenile (1-month-old) and adult (3-month-old) stages, respectively. MGcCI mice presented widespread reactive astrocytes, a decrease of synaptic markers accompanied by an increased number of parvalbumin neurons, a behavioral deficit characterized by prolonged periods of immobility, loss of weight and premature death that was partially rescued by pharmacologic depletion of microglia. Our data demonstrate that microglia development depends on mitochondrial CI and suggest a direct microglial contribution to PMDs. | es |
dc.description.sponsorship | MCIN/AEI/10.13039/501100011033, ISCIII (FORT23/00008; PI21/00915 and PI21/00915) | es |
dc.description.sponsorship | FEDER (RTI2018-096629-B-100, PID2021-126894OB-I00, SAF2017-90794-REDT and PIE13/0004) | es |
dc.description.sponsorship | Government of Andalusia (“Proyectos de Excelencia” P12-CTS-2138, P20_01312; BIOT22_00018_1, and ProyExcel_00845) co-funded by CEC, REC_EU, and FEDER funds, and by the “Ayuda de Biomedicina 2018”, Fundación Domingo Martínez | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Nature | es |
dc.relation.ispartof | Nature Metabolism. | |
dc.title | Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/acceptedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/embargoedAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Biología Celular | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Bioquímica y Biología Molecular | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Fisiología Médica y Biofísica | es |
dc.relation.projectID | FORT23/00008 | es |
dc.relation.projectID | PI21/00915 | es |
dc.relation.projectID | RTI2018-096629-B-100 | es |
dc.relation.projectID | PID2021-126894OB-I00 | es |
dc.relation.projectID | SAF2017-90794-REDT | es |
dc.relation.projectID | PIE13/0004 | es |
dc.relation.projectID | P12-CTS-2138 | es |
dc.relation.projectID | P20_01312 | es |
dc.relation.projectID | BIOT22_00018_1 | es |
dc.relation.projectID | ProyExcel_00845 | es |
dc.date.embargoEndDate | 2025-01-23 | |
dc.relation.publisherversion | https://dx.doi.org/10.1038/s42255-024-01081-0 | es |
dc.identifier.doi | 10.1038/s42255-024-01081-0 | es |
dc.journaltitle | Nature Metabolism | es |
dc.contributor.funder | Ministerio de Ciencia e Innovación (MICIN). España | es |
dc.contributor.funder | Agencia Estatal de Investigación. España | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) | es |
dc.contributor.funder | Junta de Andalucía | es |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Postprint_10.1038s42255-024-01 ... | 355.9Kb | ![]() | Este documento no está disponible a texto completo hasta el 2025-01-23 . Para más información póngase en contacto con idus@us.es. | Versión aceptada |
Este registro aparece en las siguientes colecciones
Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.